In Its Current Form, Marinol Is Delivered Through A Gel Capsule Where 90% Of The Dronabinol Is Metabolized Into 11-oh- Thc Due To The First-pass (liver) Metabolism.

Dronabinol is also used to treat loss of appetite and weight loss in patients with HIV infection. Dronabinol (also called THC) is a man-made form of the active natural substance in marijuana. AXIM will pursue these same indications in its clinical research on the chewing gum replacement. In its current form, Marinol is delivered through a gel capsule where 90% of the dronabinol is metabolized into 11-OH- THC due to the first-pass (liver) metabolism. This causes significant side effects for patients including impaired thinking and other adverse reactions. AXIM’s patented control-release chewing gum largely bypasses the first pass metabolism in the liver to the point where AXIM believes their new formulation will improve efficacy while simultaneously reducing side effects for patients who utilize this new delivery method. AXIM will work with an API-manufacturing company that will supply AXIM with the syntheticdronabinol(delta-9-THC) for use in these trials.AXIM will then conduct a bio-equivalencystudy and will eventually seek FDA approval to bring this chewing gum product medical marijuana videos to market. “AXIM has once again expanded its clinical research program in an impressive and important way that will greatly benefit this population of patients,”said Dr. Stuart Titus, PhD, CEO of Medical Marijuana, Inc. “With more than a third of patients discontinuing use of Marinol as prescribed due to adverse side effects, it is encouraging that AXIM will research and attempt to bring to market an improved medication thatmay provide expanded therapeutics while allowing for a better quality of life forthis patient population.” About AXIM AXIM Biotechnologies, Inc.

To read more visit http://finance.yahoo.com/news/medical-marijuana-inc-major-investment-131500527.html

Posted in: investing, News, stocks

Comments are closed.